Top Ten most popular articles on Pharmafile.com this week
pharmafile | October 18, 2019 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |
It’s time for a rundown of the top 10 articles on PharmaFile this past week. The past seven days saw the first and only transdermal patch for schizophrenia being approved and additionally a new UK medicines bill which could see faster access to key conditions such as dementia and Alzheimer’s. Furthermore there were three FDA approvals for a variety of different conditions.
10. Lilly’s pegilodecakin combo falls at Phase 3 in pancreatic cancer
In disappointing news, Eli Lilly has revealed that pegilodecakin, in combination with the chemotherapy regimen FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin), proved inferior to FOLFOX alone in the treatment of metastatic pancreatic cancer in patients who saw disease progression during or following a first-line gemcitabine-containing regimen, failing to meet its primary endpoint in a Phase 3 study.
9. FDA approves first and only transdermal patch for schizophrenia
Hisamitsu Pharmaceutical subsidiary Noven Pharmaceuticals has revealed the FDA approval of Secuado (asenapine) in adult schizophrenia patients, making it the first and only transdermal patch formulation available in the US for the treatment of the condition.
8. Roche’s Phase 3 Pemphix trial smashes primary endpoint for pemphigus vulgaris
Roche has revealed new Phase 3 data demonstrating that its MabThera/Rituxan (rituximab) therapy Pemphix met its primary endpoint in the treatment of moderate to severe pemphigus vulgaris (PV) in adult patients
7. New UK Medicines Bill could improve access to new dementia treatments
The Government has announced new legislation aimed at providing faster access to medicines, including those treating dementia and Alzheimer’s.
6. AstraZeneca receives FDA Priority Review for breast cancer drug
AstraZeneca have announced that the US FDA has granted Priority Review for its experimental breast cancer treatment trastuzumab.
5. FDA approves Eli Lilly’s Reyvow for treatment of migraine in adults
The US FDA has approved Eli Lily’s oral therapy Reyvow (lasmiditan) for the acute treatment of adults with migraine with or without aura, with Lilly noting that this is ‘the first and only FDA-approved medicine in a new class of serotonin (5-HT)1F receptor agonists’.
4. Takeda sheds 30 products in emerging markets in $200m deal
Takeda has sold selected prescription and over the counter products to Acino in the Near East, Middle East and Africa as it looks to trim down its debt and portfolio following its $62 billion acquisition of Shire.
3. Daiichi Sankyo show low CV events and bleeding in NVAF patients on Lixiana
Daiichi Sankyo have announced one-year follow-up results from an analysis of 12,574 European non-valvular atrial fibrillation (NVAF) patients treated with Lixiana (edoxaban).
2. FDA approves Janssen’s Xarelto for blood clot prevention
Janssen’s Xarelto (rivaroxaban) has secured FDA approval for the prevention of venous thromboembolism (VTE), or blood clots, in hospitalised acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding, it has emerged.
1. Pfizer reveals strong Phase 3 data for abrocitinib in atopic dermatitis
Pfizer confirmed over the weekend that its oral Janus kinase 1 (JAK1) inhibitor abrocitinib met all of its co-primary and key secondary endpoints in a 12-week, Phase 3 study investigating its efficacy in the treatment of moderate to severe atopic dermatitis (AD) in patients aged 12 and older.
